Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/hematol.1.001
T cell engagers targeting CD19 to treat B cell malignancies, and beyond
Xiaoqiang Yan, Ph.D1,*
- 1ITabMed Ltd. Shanghai, China
Corresponding Author
Xiaoqiang Yan,xiaoqiang.yan@itabmed.com
Received Date: January 18, 2022
Accepted Date: February 23, 2022
Yan X. T cell engagers targeting CD19 to treat B cell malignancies, and beyond. J Clin Exp Hematol. 2022;1(1):1-3.
Copyright: © 2022 Yan X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
T cell engagers targeting CD19 to treat B cell malignancies, and beyond
In the past decade, a tremendous progress has been made in developing T cell engaging bi-specific antibodies (BsAbs) targeting CD19 to treat B cell malignancies. The T cell engaging bi-specific molecule binds to CD3 on a T cell and a tumor-associated antigen (TAA) on a target cell and redirects the T cell to a specific target cell bypassing the MHC restriction mechanism, leading to the formation of immune synapse between the T cell and target cell and target cell lysis.
Commentary on “Identification of CD19 as a shared biomarker via PPARγ/β-catenin/Wnt3a pathway linking psoriasis and major depressive disorder”
This study presents a comprehensive exploration into the shared molecular mechanisms linking psoriasis and major depressive disorder (MDD), two conditions that are increasingly recognized as having potential comorbidities. It offers new insights into the immune and genetic pathways that may contribute to both disorders, emphasizing the potential of CD19 as a biomarker and therapeutic target through the PPARγ/β-catenin/Wnt3a signaling pathway.